Abstract
Objective Obesity and type 2 diabetes (DM) are risk factors for severe COVID-19 outcomes, which disproportionately affect South Asian populations. This study aims to investigate the humoral and cellular immune responses to SARS-CoV-2 in adult COVID-19 survivors with obesity and DM in Bangladesh.
Methods In this cross-sectional study, SARS-CoV-2-specific antibody and T cell responses were investigated in 63 healthy and 75 PCR-confirmed COVID-19 recovered individuals in Bangladesh, during the pre-vaccination first wave of the COVID-19 pandemic in 2020.
Results In COVID-19 survivors, SARS-CoV-2 infection induced robust antibody and T cell responses, which correlated with disease severity. After adjusting for age, sex, DM status, disease severity, and time since onset of symptoms, obesity was associated with decreased neutralising antibody titers, and increased SARS-CoV-2 spike-specific IFN-γ response along with increased proliferation and IL-2 production by CD8+ T cells. In contrast, DM was not associated with SARS-CoV-2-specific antibody and T cell responses after adjustment for obesity and other confounders.
Conclusions Obesity is associated with lower neutralising antibody levels and higher T cell responses to SARS-CoV-2 post COVID-19 recovery, while antibody or T cell responses remain unaltered in DM.
What is already known about this subject?
The impact of obesity and diabetes mellitus (DM) on COVID-19 severity and mortality is disproportionately high in South Asian populations.
People with obesity and DM experience reduced protection against COVID-19 after vaccination.
What are the new findings in your manuscript?
Despite similar IgG antibody levels, adults with overweight/obesity (BMI ≥ 23 kg/m2) have lower neutralising antibody capacity and higher T cell responses to SARS-CoV-2 following COVID-19 recovery.
Antigen-specific antibody and T cell responses are preserved in individuals with DM who survive SARS-CoV-2 infection.
How might your results change the direction of research or the focus of clinical practice?
Our findings underscore the critical need to understand the mechanisms underlying the diminished neutralising capacity of antibodies in obesity, as this has profound implications for the development of effective interventions and treatments for COVID-19.
Our study highlights the significance of T cells in COVID-19 survivors with obesity, indicating their potential role in informing the development of next-generation vaccines against coronaviruses.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MA is funded by Prime Minister Fellowship, Bangladesh and supported by Bangladesh Medical Research Council. SJD is funded by an NIHR Global Research Professorship (NIHR300791), PK and EB are NIHR Senior Investigators, and SJD, PK, EB and MC are part of the NIHR Oxford Biomedical Research Centre. PK is funded by WT109965MA. FRC is funded by BSMMU Research grant (BSMMU/2021/5567). AT is supported by the EU's Horizon2020 Marie Sklodowska-Curie Fellowship (FluPRINT, grant number 796636). TdS is funded by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z). The Wellcome Center for Human Genetics is supported by the Wellcome Trust (grant 090532/Z/09/Z). LT is supported by the Wellcome Trust (grant number 205228/Z/16/Z), the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections (EZI) (NIHR200907), and the Centre of Excellence in Infectious Diseases Research (CEIDR) and the Alder Hey Charity. MC and LT are supported by the US Food and Drug Administration Medical Countermeasures Initiative contract 75F40120C00085. MC is supported by the Oak Foundation. SPar is supported by Bangladesh Medical Research Council. Some reagents including peptides for the T cell assays were supplied by the PITCH Consortium, with funding from UK Department of Health and Social Care, UKRI Medical Research Council (MR/W02067X/1 and MR/T025611/1) and the Huo Family Foundation. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care, Public Health England, or the US Food and Drug Administration.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Oxford Tropical Research Ethics Committee of the University of Oxford, United Kingdom, the Ethical Review Committee of the Dhaka Medical College Hospital, Bangladesh and the Institutional Review Board of the Bangabandhu Sheikh Mujib Medical University, Bangladesh gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
